TARSUS PHARMACEUTICALS, INC. Operating Lease Cost
TARSUS PHARMACEUTICALS, INC. (TARS) reported Operating Lease Cost of $639.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2026-06-30 was $639.00K, a 249.18% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2026-03-31 was $802.00K, a 363.58% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2025-12-31 was $960.00K, a 338.36% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2025-09-30 was $174.00K, a 20.18% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $1.49M, a 78.44% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $835.00K, a 18.44% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $705.00K, a 23.90% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $569.00K, a 47.79% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $639.00K 10-Q · filed 2026-08-06 | $1.44M 10-Q · filed 2026-08-06 | $2.40M derived: sum of 3 quarters · filed 2026-08-06 | $2.58M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $802.00K 10-Q · filed 2026-05-06 | $1.76M derived: sum of 2 quarters · filed 2026-05-06 | $1.94M derived: sum of 3 quarters · filed 2026-05-06 | $2.12M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.13M derived: sum of 2 quarters · filed 2026-02-23 | $1.32M derived: sum of 3 quarters · filed 2026-08-06 | $1.49M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $174.00K 10-Q · filed 2025-11-04 | $357.00K derived: sum of 2 quarters · filed 2026-08-06 | $530.00K 10-Q · filed 2025-11-04 | $749.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $183.00K 10-Q · filed 2026-08-06 | $356.00K 10-Q · filed 2026-08-06 | $575.00K derived: sum of 3 quarters · filed 2026-08-06 | $793.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $173.00K 10-Q · filed 2026-05-06 | $392.00K derived: sum of 2 quarters · filed 2026-05-06 | $610.00K derived: sum of 3 quarters · filed 2026-05-06 | $829.00K derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $437.00K derived: sum of 2 quarters · filed 2026-02-23 | $656.00K derived: sum of 3 quarters · filed 2026-02-23 | $835.00K 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $218.00K 10-Q · filed 2025-11-04 | $437.00K derived: sum of 2 quarters · filed 2025-11-04 | $616.00K 10-Q · filed 2025-11-04 | $796.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $219.00K 10-Q · filed 2025-08-06 | $398.00K 10-Q · filed 2025-08-06 | $578.00K derived: sum of 3 quarters · filed 2026-02-23 | $757.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | $179.00K 10-Q · filed 2025-05-01 | $359.00K derived: sum of 2 quarters · filed 2026-02-23 | $538.00K derived: sum of 3 quarters · filed 2026-02-23 | $714.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $359.00K derived: sum of 2 quarters · filed 2026-02-23 | $535.00K derived: sum of 3 quarters · filed 2026-02-23 | $705.00K 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $179.00K 10-Q · filed 2024-11-13 | $355.00K derived: sum of 2 quarters · filed 2024-11-13 | $525.00K 10-Q · filed 2024-11-13 | $667.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $176.00K 10-Q · filed 2024-08-08 | $346.00K 10-Q · filed 2024-08-08 | $488.00K derived: sum of 3 quarters · filed 2025-02-25 | $630.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $170.00K 10-Q · filed 2024-05-08 | $312.00K derived: sum of 2 quarters · filed 2025-02-25 | $454.00K derived: sum of 3 quarters · filed 2025-02-25 | $596.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $284.00K derived: sum of 2 quarters · filed 2025-02-25 | $426.00K derived: sum of 3 quarters · filed 2025-02-25 | $569.00K 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $142.00K 10-Q · filed 2023-11-09 | $284.00K derived: sum of 2 quarters · filed 2023-11-09 | $427.00K 10-Q · filed 2023-11-09 | $574.00K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $142.00K 10-Q · filed 2023-08-10 | $285.00K 10-Q · filed 2023-08-10 | $432.00K derived: sum of 3 quarters · filed 2023-08-10 | $550.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $143.00K 10-Q · filed 2022-05-11 | $290.00K derived: sum of 2 quarters · filed 2023-03-17 | $408.00K derived: sum of 3 quarters · filed 2023-03-17 | $468.00K derived: sum of 4 quarters · filed 2023-03-17 | |||
| 2021-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $265.00K derived: sum of 2 quarters · filed 2023-03-17 | $325.00K derived: sum of 3 quarters · filed 2023-03-17 | $385.00K 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $118.00K 10-Q · filed 2022-11-09 | $178.00K derived: sum of 2 quarters · filed 2022-11-09 | $238.00K 10-Q · filed 2022-11-09 | $313.00K derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $60.00K 10-Q · filed 2022-08-11 | $120.00K 10-Q · filed 2022-08-11 | $195.00K derived: sum of 3 quarters · filed 2022-08-11 | $274.00K derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $60.00K 10-Q · filed 2022-05-11 | $135.00K derived: sum of 2 quarters · filed 2022-05-11 | $214.00K derived: sum of 3 quarters · filed 2022-05-11 | $252.00K derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $154.00K derived: sum of 2 quarters · filed 2022-03-14 | $192.00K derived: sum of 3 quarters · filed 2022-03-14 | $208.00K 10-K · filed 2022-03-14 | $200.00K 10-K · filed 2021-03-31 | ||
| 2020-09-30 | $79.00K 10-Q · filed 2021-11-10 | $100.00K 10-Q · filed 2020-11-25 | $117.00K derived: sum of 2 quarters · filed 2021-11-10 | $133.00K 10-Q · filed 2021-11-10 | $100.00K 10-Q · filed 2020-11-25 | $197.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $38.00K 10-Q · filed 2021-08-05 | $53.00K 10-Q · filed 2021-08-05 | $118.00K derived: sum of 3 quarters · filed 2021-08-05 | $134.00K derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | $16.00K 10-Q · filed 2021-05-11 | $80.00K derived: sum of 2 quarters · filed 2021-05-11 | $96.00K derived: sum of 3 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $80.00K derived: sum of 2 quarters · filed 2021-03-31 | $100.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $16.00K 10-Q · filed 2020-11-25 | $36.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |